転移性または切除不能ながんに対する通常の化学療法治療(カペシタビン)への抗がん剤ZEN003694の追加の試験
固形腫瘍患者におけるカペシタビンと併用したZEN003694(ZEN-3694)の第I相試験
This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with the usual treatment with capecitabine in treating patients with cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable) and that it has progressed on previous standard treatment. ZEN003694 is an inhibitor of a family of proteins called the bromodomain and extra-terminal (BET). It may prevent the growth of tumor cells that over produce BET protein. Capecitabine is in a class of medications called antimetabolites. It is taken up by cancer cells and breaks down into fluorouracil, a substance that kills cancer cells. Giving ZEN003694 in combination with capecitabine may be safe in treating patients with metastatic or unresectable solid tumors.
調査の概要
状態
詳細な説明
PRIMARY OBJECTIVE:
I. To determine the safety and tolerability, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of BET bromodomain inhibitor ZEN-3694 (ZEN003694 [ZEN-3694]) in combination with capecitabine in patients with solid tumors.
SECONDARY OBJECTIVES:
I. To observe and record anti-tumor activity of ZEN003694 (ZEN-3694) in combination with capecitabine.
II. To determine the pharmacokinetics (PK) of ZEN003694 (ZEN-3694) in combination with capecitabine.
III. To determine the pharmacodynamics (PD) of ZEN003694 (ZEN-3694) in combination with capecitabine (death receptor 5 [DR5] dynamics and apoptosis).
IV. To identify molecular subpopulations particularly sensitized to bromodomain and extra-terminal motif inhibitor (BETi) and capecitabine.
OUTLINE: This is a dose-escalation study of ZEN003694 and capecitabine, followed by a dose-expansion study.
Patients receive ZEN003694 orally (PO) once daily (QD) and capecitabine PO twice daily (BID) 2 weeks on, 1 week off during each treatment cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. NOTE: Patients do not receive ZEN003694 on day 1 of cycle 1. Patients undergo computed tomography (CT) or magnetic resonance imaging (MRI), positron emission tomography (PET)/CT, and collection of blood samples throughout the trial. Patients may also undergo biopsies during screening and while on the study.
After completion of study treatment, patients are followed up for safety 30 days after the last dose, and then every 3 months for 12 months.
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
California
-
Irvine、California、アメリカ、92612
- 募集
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
-
コンタクト:
- Site Public Contact
- 電話番号:877-827-8839
- メール:ucstudy@uci.edu
-
主任研究者:
- Fa-Chyi Lee
-
Orange、California、アメリカ、92868
- 募集
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:877-827-8839
- メール:ucstudy@uci.edu
-
主任研究者:
- Fa-Chyi Lee
-
-
Florida
-
Gainesville、Florida、アメリカ、32610
- 募集
- UF Health Cancer Institute - Gainesville
-
コンタクト:
- Site Public Contact
- 電話番号:352-273-8010
- メール:cancer-center@ufl.edu
-
主任研究者:
- Thomas J. George
-
-
Illinois
-
Shiloh、Illinois、アメリカ、62269
- 積極的、募集していない
- Memorial Hospital East
-
-
Kansas
-
Fairway、Kansas、アメリカ、66205
- 募集
- University of Kansas Clinical Research Center
-
コンタクト:
- Site Public Contact
- 電話番号:913-588-3671
- メール:KUCC_Navigation@kumc.edu
-
主任研究者:
- Joaquina C. Baranda
-
Kansas City、Kansas、アメリカ、66160
- 募集
- University of Kansas Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:913-588-3671
- メール:KUCC_Navigation@kumc.edu
-
主任研究者:
- Joaquina C. Baranda
-
Westwood、Kansas、アメリカ、66205
- 募集
- University of Kansas Hospital-Westwood Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:913-588-3671
- メール:KUCC_Navigation@kumc.edu
-
主任研究者:
- Joaquina C. Baranda
-
-
Missouri
-
City of Saint Peters、Missouri、アメリカ、63376
- 積極的、募集していない
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur、Missouri、アメリカ、63141
- 積極的、募集していない
- Siteman Cancer Center at West County Hospital
-
St Louis、Missouri、アメリカ、63110
- 積極的、募集していない
- Washington University School of Medicine
-
St Louis、Missouri、アメリカ、63129
- 積極的、募集していない
- Siteman Cancer Center-South County
-
St Louis、Missouri、アメリカ、63136
- 積極的、募集していない
- Siteman Cancer Center at Christian Hospital
-
-
New York
-
New York、New York、アメリカ、10032
- 募集
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
主任研究者:
- Ryan Moy
-
コンタクト:
- Site Public Contact
- 電話番号:212-342-5162
- メール:cancerclinicaltrials@cumc.columbia.edu
-
The Bronx、New York、アメリカ、10461
- 募集
- Montefiore Medical Center-Einstein Campus
-
コンタクト:
- Site Public Contact
- 電話番号:718-379-6866
- メール:eskwak@montefiore.org
-
主任研究者:
- Chaoyuan Kuang
-
The Bronx、New York、アメリカ、10467
- 募集
- Montefiore Medical Center - Moses Campus
-
コンタクト:
- Site Public Contact
- 電話番号:718-379-6866
- メール:eskwak@montefiore.org
-
主任研究者:
- Chaoyuan Kuang
-
The Bronx、New York、アメリカ、10461
- 募集
- Montefiore Medical Center-Weiler Hospital
-
コンタクト:
- Site Public Contact
- 電話番号:718-379-6866
- メール:eskwak@montefiore.org
-
主任研究者:
- Chaoyuan Kuang
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45219
- 募集
- University of Cincinnati Cancer Center-UC Medical Center
-
コンタクト:
- Site Public Contact
- 電話番号:513-584-7698
- メール:cancer@uchealth.com
-
主任研究者:
- Davendra P. Sohal
-
West Chester、Ohio、アメリカ、45069
- 募集
- University of Cincinnati Cancer Center-West Chester
-
コンタクト:
- Site Public Contact
- 電話番号:513-584-7698
- メール:cancer@uchealth.com
-
主任研究者:
- Davendra P. Sohal
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73104
- 募集
- University of Oklahoma Health Sciences Center
-
コンタクト:
- Site Public Contact
- 電話番号:405-271-8777
- メール:ou-clinical-trials@ouhsc.edu
-
主任研究者:
- Susanna V. Ulahannan
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、アメリカ、15232
- 募集
- UPMC Hillman Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:412-647-8073
-
主任研究者:
- Anwaar Saeed
-
-
Tennessee
-
Nashville、Tennessee、アメリカ、37232
- 募集
- Vanderbilt University/Ingram Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:800-811-8480
-
主任研究者:
- Thatcher R. Heumann
-
Nashville、Tennessee、アメリカ、37204
- 募集
- Vanderbilt Breast Center at One Hundred Oaks
-
コンタクト:
- Site Public Contact
- 電話番号:800-811-8480
-
主任研究者:
- Thatcher R. Heumann
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Dose Escalation additional criteria: Patients must have histologically confirmed cancer that is metastatic or unresectable and must have progressed on standard therapies which would have included fluorouracil (5-FU) or capecitabine
- Dose Escalation additional criteria specifically for colorectal cancer (CRC) patients: Willingness and ability to undergo a pre-treatment biopsy
- Dose Expansion additional criteria: Patients must have histologically confirmed CRC that is metastatic or unresectable and must have progressed on standard therapies which would have included 5-FU or capecitabine
- Dose Expansion additional criteria: Willingness and ability to undergo pre- and on- treatment biopsies
- Patients must have measurable disease
- Age >= 18 years. Because no dosing or adverse event data are currently available on the use of ZEN003694 (ZEN-3694) in combination with capecitabine in patients < 18 years of age, children are excluded from this study
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (Karnofsky >= 60%)
- Availability of archival tumor tissue at the time of patient enrollment for molecular profiling studies
- Prior to study dosing, previous systemic therapy must have been completed for at least five half-lives or 2 weeks, whichever is shorter
- Absolute neutrophil count >= 1,000/mcL
- Platelets >= 100,000/mcL
- Total bilirubin =< 1.5 institutional upper limit of normal (ULN)
- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN
- Glomerular filtration rate (GFR) >= 50 mL/min/1.73 m^2
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
- Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- Patients should be New York Heart Association Functional Classification of class 2B or better
- The effects of ZEN003694 (ZEN-3694) and capecitabine on the developing human fetus are unknown. For this reason and because BET inhibitors as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Women of child-bearing potential and men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of ZEN003694 (ZEN-3694) and capecitabine administration
- Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants
Exclusion Criteria:
- Previous treatment with BET inhibitors
- History of inability to tolerate capecitabine at the projected treatment dose on this trial
- Use of oral Factor Xa inhibitors (i.e., rivaroxaban, apixaban, betrixaban, edoxaban otamixaban, letaxaban, eribaxaban) and Factor IIa inhibitors (i.e., dabigatran). Low molecular weight heparin is allowed
- Treatment for HIV, hepatitis B or hepatitis C only if this interferes with the current treatment (e.g. through drug-drug interactions)
- Gastrointestinal pathology or history that adversely impacts the ability to take or absorb oral medication
- Hepatic tumor burden > 30% or peritoneal carcinomatosis
- Untreated/uncontrolled central nervous system (CNS) disease
- Known dihydropyrimidine dehydrogenase (DPD) deficiency
- Severe intercurrent illness or comorbidity
- Inability to comply with the protocol and/or not willing or who will not be available for follow-up assessments
- Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia and neuropathy up to and including grade 2
- Patients who are receiving any other investigational agents
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to ZEN003694 (ZEN-3694) or other agents used in study
- Patients receiving any medications or substances that are strong inhibitors or inducers of CYP3A4 are ineligible. Strong inhibitors of CYP3A4 must be discontinued at least 7 days, and inducers 14 days prior to the first dose of ZEN003694 and capecitabine. Substrates of CYP1A2 with narrow therapeutic window must be avoided while taking ZEN003694
- Pregnant women are excluded from this study because ZEN003694 (ZEN-3694) is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with ZEN003694 (ZEN-3694), breastfeeding should be discontinued if the mother is treated with ZEN003694 (ZEN-3694). These potential risks may also apply to other agents used in this study
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Treatment (ZEN003694, capecitabine)
Patients receive ZEN003694 PO QD and capecitabine PO BID 2 weeks on, 1 week off during each treatment cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. NOTE: Patients do not receive ZEN003694 on day 1 of cycle 1. Patients undergo CT or MRI, PET/CT, and collection of blood samples throughout the trial. Patients may also undergo biopsies during screening and while on the study. |
Undergo MRI
他の名前:
Undergo biopsy
他の名前:
Undergo collection of blood samples
他の名前:
Undergo PET/CT
他の名前:
Given PO
他の名前:
Given PO
他の名前:
Undergo CT and PET/CT
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of adverse events
時間枠:Up to 30 days after last dose
|
Adverse events and serious adverse events will be tabulated for each dose levels. As per National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0, the term toxicity is defined as adverse events that are classified as either possibly, probably, or definitely related to study treatment. The maximum grade for each type of toxicity will be recorded for each patient, and frequency tables will be reviewed to determine toxicity patterns. |
Up to 30 days after last dose
|
|
Maximum tolerated dose (MTD)
時間枠:During the first cycle of therapy (Cycles = 21 days)
|
Defined as the highest dose level with no more than 1/6 dose-limiting toxicity. Dose level 4 was selected as the MTD. |
During the first cycle of therapy (Cycles = 21 days)
|
|
Recommended phase 2 dose (RP2D)
時間枠:Up to 30 days after last dose
|
Dose level 4 was selected as the RP2D. |
Up to 30 days after last dose
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Anti-tumor activity of ZEN003694 (ZEN-3694) in combination with capecitabine
時間枠:Up to 12 months
|
Treatment response will be assessed for all patients based on Response Evaluation Criteria in Solid Tumors version 1.1: complete response (CR), partial response (PR), stable disease (SD), and progression of disease (PD). Clinical benefit rate is defined as the addition of CR, PR and SD. |
Up to 12 months
|
|
Progression free survival (PFS)
時間枠:Up to 12 months
|
PFS will be estimated by the Kaplan-Meier method, along with 95% confidence regions. |
Up to 12 months
|
|
Objective response rate (ORR)
時間枠:Up to 12 months
|
Defined as the addition of CR and PR. The probability of ORR and clinical benefit rate will be estimated with exact 95% binomial confidence intervals. |
Up to 12 months
|
|
Pharmacokinetics (PK) of ZEN003694 (ZEN-3694) in combination with capecitabine
時間枠:Up to 12 months
|
Will determine the PK of ZEN003694 (ZEN-3694) in combination with capecitabine. Capecitabine PK will be evaluated in the absence and presence of ZEN003694 (ZEN-3694) and Cmax and area under curve (AUC) will be compared with a paired test. ZEN003694 (ZEN-3694) PK will be evaluated in the presence of capecitabine and Cmax and AUC will be compared descriptively with historical data. |
Up to 12 months
|
|
Pharmacodynamics (PD) of ZEN003694 (ZEN-3694) in combination with capecitabine
時間枠:Up to 12 months
|
Will determine PD of ZEN003694 (ZEN-3694) in combination with capecitabine. Ribonucleic acid sequencing of death receptor 5 (DR5). DR5 is expected to be increased by the combination ZEN003694 (ZEN-3694) in combination with capecitabine. Pre-post comparisons will be made within patients enrolled on the expansion cohort using a non-parametric paired test, at a significance level (alpha) of 0.05. Apoptosis by Pharmacodynamic Assay Development and Implementation Section (PADIS) lab. Panel 3 is priority, but other panels will be evaluated with remaining lysate. Apoptosis is expected to be increased by the combination ZEN003694 (ZEN-3694) in combination with capecitabine. Pre-post comparisons will be made within patients enrolled on the expansion cohort using a non-parametric paired test, at a significance level (alpha) of 0.05. |
Up to 12 months
|
|
Molecular subpopulations particularly sensitized to BETi and capecitabine
時間枠:Up to 12 months
|
Will identify molecular subpopulations particularly sensitized to BETi and capecitabine. Based on WES of archival tissue, we will evaluate descriptively any mutations in genes relevant to DNA damage repair, signaling and (fluoropyrimidine) metabolism, any relations with peculiar response and/or toxicity. |
Up to 12 months
|
協力者と研究者
捜査官
- 主任研究者:Anwaar Saeed、University of Pittsburgh Cancer Institute LAO
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 病理学的プロセス
- 部位別新生物
- 新生物
- 腸の病気
- 消化器腫瘍
- 消化器系腫瘍
- 消化器系疾患
- 消化器疾患
- 腸の腫瘍
- 直腸疾患
- 結腸疾患
- 腫瘍性プロセス
- 病理学的状態、徴候および症状
- 結腸直腸腫瘍
- 新生物転移
- 複素環化化合物、1リング
- 複素環化化合物
- 調査手法
- 臨床検査技術
- 診断技術と手順
- 診断
- 外科的処置、手術
- 細胞学的技術
- 核酸、ヌクレオチド、およびヌクレオシド
- 細胞診断
- デオキシシチジン
- シチジン
- ピリミジンヌクレオシド
- ピリミジン
- 診断技術、外科的
- 化学技術、分析
- スペクトル分析
- ヌクレオシド
- ウラシル
- ピリミジノン
- デオキシリボヌクレオシド
- フルオロウラシル
- カペシタビン
- 生検
- 標本処理
- 磁気共鳴分光法
その他の研究ID番号
- NCI-2023-02652
- UM1CA186690 (米国 NIH グラント/契約)
- 10579 (その他の識別子:CTEP)
- NCI-2023-02652 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- HCC 23-096
- 10579 (その他の識別子:UPMC Hillman Cancer Center LAO)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
"NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page."
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。